Traws Pharma Sets Virtual 2025 Annual Meeting, Key Compensation Votes Ahead

TL;DR

**TRAW's virtual annual meeting is a rubber stamp for board-backed proposals, but watch the 'say-on-pay' frequency for future activist leverage.**

AI Summary

Traws Pharma, Inc. (TRAW) is holding its 2025 Annual Meeting of Stockholders on November 21, 2025, virtually, to address several key proposals. Shareholders will vote on the election of seven directors, the amendment and restatement of the Company's 2021 Incentive Compensation Plan, and a non-binding advisory vote on named executive officer compensation. Additionally, a non-binding advisory vote on the frequency of future 'say-on-pay' votes is on the agenda, with the Board recommending 'Every Two Years.' The ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, is also proposed. The company reported 7,125,832 shares of common stock outstanding as of the October 2, 2025 record date, with each share entitled to one vote. The Board of Directors recommends a 'For' vote on all proposals, including the director nominees and the 'Every Two Years' frequency for executive compensation votes. The virtual format aims to provide a consistent and convenient experience for all stockholders.

Why It Matters

This DEF 14A filing outlines critical governance and compensation decisions for Traws Pharma, directly impacting investor confidence and executive incentives. The proposed amendment to the 2021 Incentive Compensation Plan could alter future equity grants, influencing employee retention and motivation in a competitive biotech landscape. The 'say-on-pay' vote provides a direct channel for shareholders to express their views on executive compensation, a key factor in corporate governance and a potential indicator of future shareholder activism. The virtual meeting format, while convenient, also shifts the dynamic of shareholder engagement, potentially affecting the depth of interaction with management.

Risk Assessment

Risk Level: low — The filing primarily details routine annual meeting proposals, such as director elections and auditor ratification, which are standard corporate governance items. While the 2021 Incentive Compensation Plan amendment could dilute existing shares, the document does not present any immediate, specific financial or operational risks, focusing instead on procedural matters for the November 21, 2025 meeting.

Analyst Insight

Investors should review the full proxy statement for details on the 2021 Incentive Compensation Plan amendment and executive compensation to understand potential dilution and incentive structures. Voting 'Every Two Years' for say-on-pay frequency, as recommended by the Board, could reduce the frequency of direct shareholder input on executive pay, so shareholders should consider their stance carefully.

Key Numbers

• 7,125,832 — Common Stock Shares Outstanding (As of the October 2, 2025 Record Date, each entitled to one vote.)
• 6,737.1410 — Series C Preferred Stock Shares Outstanding (As of the October 2, 2025 Record Date, not entitled to vote.)
• 7 — Number of Directors (Proposed for election until the 2026 Annual Meeting.)
• 2025 — Fiscal Year for Auditor Ratification (KPMG LLP selected for the fiscal year ending December 31, 2025.)
• 33 1/3% — Quorum Requirement (Percentage of shares entitled to vote required for a quorum at the Annual Meeting.)
• November 20, 2025 — Proxy Voting Deadline (11:59 p.m. Eastern Time for Internet and telephone votes.)
• October 8, 2025 — Proxy Materials Mailing Date (Date Notice of Internet Availability of Proxy Materials was mailed.)
• 9:00 a.m. ET — Annual Meeting Start Time (On Friday, November 21, 2025.)

Key Players & Entities

• Traws Pharma, Inc. (company) — Registrant and issuer of DEF 14A
• KPMG LLP (company) — Independent registered public accounting firm for fiscal year ending December 31, 2025
• Iain Dukes (person) — Chief Executive Officer of Traws Pharma, Inc.
• Securities and Exchange Commission (regulator) — Regulator of proxy statement filings
• $7,125,832 (dollar_amount) — Shares of common stock outstanding on October 2, 2025
• $6,737.1410 (dollar_amount) — Shares of Series C Non-Voting Convertible Preferred Stock outstanding on October 2, 2025
• November 21, 2025 (date) — Date of the 2025 Annual Meeting of Stockholders
• October 2, 2025 (date) — Record date for stockholders entitled to vote at the Annual Meeting
• 2021 Incentive Compensation Plan (other) — Plan proposed for amendment and restatement
• Delaware (other) — State of incorporation for Traws Pharma, Inc.

FAQ

Industry Context

Traws Pharma operates within the pharmaceutical industry, a sector characterized by significant research and development investment, stringent regulatory oversight from bodies like the FDA, and a competitive landscape driven by innovation and patent protection. The industry is constantly evolving with advancements in biotechnology, personalized medicine, and global health challenges, requiring companies to adapt their strategies and product pipelines.

Regulatory Implications

As a pharmaceutical company, Traws Pharma is subject to extensive regulatory scrutiny regarding drug development, clinical trials, manufacturing, and marketing. Compliance with FDA regulations and international equivalents is paramount, and any failures can lead to significant fines, product recalls, or delays in market access, impacting financial performance and reputation.

What Investors Should Do

1. Review the director nominees and vote 'For' their election to ensure experienced leadership continues to guide the company.
2. Consider the proposed amendment and restatement of the 2021 Incentive Compensation Plan and vote 'For' its adoption.
3. Vote on the advisory 'Say-on-Pay' proposal regarding executive compensation, reflecting shareholder sentiment on compensation practices.
4. Vote on the frequency of future 'Say-on-Pay' votes, with the Board recommending 'Every Two Years'.
5. Ratify the appointment of KPMG LLP as the independent auditor for fiscal year 2025 to ensure financial transparency and integrity.

Key Dates

• 2025-11-21: 2025 Annual Meeting of Stockholders — Stockholders will vote on director elections, incentive plan amendments, executive compensation, auditor ratification, and meeting adjournment.
• 2025-10-02: Record Date — Determined which stockholders are entitled to receive notice of and vote at the Annual Meeting.
• 2025-10-08: Proxy Materials Mailing Date — Indicates when shareholders received notice of the availability of proxy materials, initiating the proxy voting period.
• 2025-11-20: Proxy Voting Deadline — The deadline for submitting votes via internet or telephone, crucial for ensuring shareholder votes are counted.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about the matters to be voted on at a company's annual meeting of shareholders. (This document contains the information presented in this analysis, outlining proposals and executive compensation details for Traws Pharma, Inc.)

Named Executive Officers (NEOs)

The top executive officers of a company, typically including the CEO, CFO, and other highest-paid executives, whose compensation is disclosed in detail in SEC filings. (Their compensation is a key item for shareholder vote and advisory review in this DEF 14A filing.)

Say-on-Pay Vote

A non-binding shareholder vote on the compensation of the company's named executive officers. (Traws Pharma is seeking shareholder approval on this matter and also on the frequency of these votes.)

Independent Registered Public Accounting Firm

An external audit firm hired by a company to conduct an independent audit of its financial statements. (Shareholders are asked to ratify the selection of KPMG LLP for the fiscal year ending December 31, 2025.)

Quorum

The minimum number of shares that must be represented at a meeting for business to be legally transacted. (A quorum requirement of 33 1/3% of shares entitled to vote is necessary for the Annual Meeting to proceed.)

Year-Over-Year Comparison

This analysis is based on the 2025 DEF 14A filing. Direct comparison to a previous filing (e.g., 2024 DEF 14A) for metrics like revenue growth, margin changes, or new risks is not possible with the provided text. However, the inclusion of proposals for director elections, incentive plan amendments, executive compensation votes, and auditor ratification are standard components of annual proxy statements, indicating continuity in corporate governance processes.

Filing Documents

• tm2527912-1_def14a.htm (DEF 14A) — 943KB
• lg_trawspharma-4clr.jpg (GRAPHIC) — 12KB
• px_25trawsproxy1pg01-bw.jpg (GRAPHIC) — 270KB
• px_25trawsproxy1pg02-bw.jpg (GRAPHIC) — 201KB
• 0001104659-25-097926.txt ( ) — 2989KB
• traw-20241231.xsd (EX-101.SCH) — 10KB
• traw-20241231_def.xml (EX-101.DEF) — 4KB
• traw-20241231_lab.xml (EX-101.LAB) — 36KB
• traw-20241231_pre.xml (EX-101.PRE) — 6KB
• tm2527912-1_def14a_htm.xml (XML) — 215KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 38 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 41

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 43 PAY VERSUS PERFORMANCE 49 OTHER MATTERS 54 APPENDIX A A-1 i TABLE OF CONTENTS Traws Pharma, Inc. 12 Penns Trail Newtown, PA 18940 USA (267) 759-3680 PROXY STATEMENT ANNUAL MEETING OF STOCKHOLDERS TO BE HELD NOVEMBER 21, 2025 GENERAL INFORMATION This Proxy Statement is furnished to stockholders of Traws Pharma, Inc., a Delaware corporation ("we," "us," or the "Company"), in connection with the solicitation by our Board of Directors ("Board") of proxies for use at our 2025 Annual Meeting of Stockholders (the "Annual Meeting"). The Annual Meeting is scheduled to be held at 9:00 a.m. Eastern Time on Friday, November 21, 2025, at a virtual location. We have adopted a virtual format for our Annual Meeting to provide a healthy, consistent, and convenient experience to all stockholders, regardless of location. You may attend the Annual Meeting virtually via the Internet at www.virtualshareholdermeeting.com/TRAW2025, where you will be able to vote electronically and submit questions for management's consideration. You may also attend the Annual Meeting and submit your vote by proxy and may submit questions ahead of the Annual Meeting through the designated website. For further information, please see the Questions and Answers about the Annual Meeting starting on page 2 of this Proxy Statement. At the Annual Meeting, stockholders will be asked to consider and vote upon: 1. The election of seven directors, each to hold office until our 2026 Annual Meeting of Stockholders and until his or her successor is elected and qualified; 2. A proposal to adopt and approve the amendment and restatement of the Company's 2021 Incentive Compensation Plan, as amended and restated; 3. A proposal to approve, on a non-binding advisory basis, the compensation of our named executive officers; 4. A proposal to approve, on a non-binding advisory basis, the frequency of holding an advisory vote to approve the compensation of

View Full Filing

View this DEF 14A filing on SEC EDGAR